CMS makes it official, codifying Medicare drug price negotiations established under IRA

The Centers for Medicare & Medicaid Services has finalized a rule codifying the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act, according to coverage from Fierce Pharma and the American Hospital Association. Bloomberg Law News reports that the Trump administration has finalized its plan for the fourth round of Medicare drug price negotiations, moving the program forward under new leadership. The Mountain Press frames the development as Washington's drug price controls threatening medical innovation, while RealClearHealth warns that a Medicare rule could cost cancer patients their time. TradingView notes that Halozyme Therapeutics projects zero to minimal royalty impact through 2035, suggesting limited near-term financial exposure for at least one manufacturer. Coverage does not yet specify which drugs will be included in the fourth negotiation cycle or the exact timeline for price implementation.

The American Hospital Association's coverage emphasizes that CMS has made the negotiation program official through formal rulemaking, giving the policy durable regulatory status rather than relying on prior guidance alone. Fierce Pharma's headline confirms the codification directly ties the program to the Inflation Reduction Act's statutory framework. Bloomberg Law News highlights the fourth negotiation cycle as the immediate next phase, indicating the program is advancing on schedule despite the change in administration. The Mountain Press and RealClearHealth offer critical perspectives, focusing on potential consequences for innovation and patient access to care, particularly for cancer patients. TradingView's inclusion of Halozyme Therapeutics suggests market participants are assessing royalty exposure, though the company projects minimal impact through 2035.

The Medicare Drug Price Negotiation Program was established under the Inflation Reduction Act, which authorized the federal government to negotiate prices for certain high-cost drugs covered by Medicare for the first time. Codification through a final CMS rule embeds the program in federal regulation, making it more resistant to reversal through informal policy shifts. The fourth negotiation cycle represents an expansion of the program's scope beyond its initial set of drugs, though coverage does not state how many drugs will be selected or which therapeutic categories will be prioritized. The stakes involve federal spending on Medicare, pharmaceutical revenue, patient out-of-pocket costs, and industry investment decisions in research and development.

Readers should watch for CMS to announce the specific drugs selected for the fourth negotiation cycle and the published maximum fair prices that result. Coverage does not indicate whether legal challenges to the codified rule are pending or planned, nor does it state how the Trump administration's broader health policy agenda may affect future negotiation rounds. Halozyme Therapeutics' projection of zero to minimal royalty impact through 2035 offers one data point on industry exposure, but coverage does not provide comparable estimates from other manufacturers. Patient access concerns raised by RealClearHealth, particularly regarding cancer patients, may shape subsequent commentary and oversight as negotiated prices take effect.